Core Insights - Altimmune, Inc. has appointed Linda M. Richardson as Chief Commercial Officer, effective September 16, 2025, bringing over 30 years of experience in sales, marketing, and business development across various therapeutic areas [1][2] - The appointment is seen as a strategic move as the company approaches the initiation of Phase 3 development of pemvidutide for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [2] - Richardson believes pemvidutide has significant potential to improve patient outcomes in hepato-metabolic diseases and sees opportunities in Alcohol Use Disorder and Alcohol-associated Liver Disease [2] Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases [5] - The lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist targeting MASH, Alcohol Use Disorder, Alcohol-associated Liver Disease, and obesity [5] Inducement Grant Details - As part of her appointment, Richardson will receive options to purchase 278,000 shares and 96,000 restricted stock units (RSUs) [3][4] - The options will vest over four years, with one-fourth vesting on the one-year anniversary of the grant date [3][4]

Core Insights - Class actions have been initiated for stockholders of Altimmune, Inc. and SelectQuote, Inc. with deadlines for lead plaintiff petitions approaching [1] Altimmune, Inc. (NASDAQ:ALT) - The class period for Altimmune is from August 10, 2023, to June 25, 2025, with a lead plaintiff deadline of October 6, 2025 [2] - On June 26, 2025, Altimmune announced disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide, failing to achieve statistical significance in the primary endpoint of fibrosis reduction due to a higher-than-expected placebo response [2] - Following the announcement, Altimmune's stock price plummeted from $7.71 to $3.61 per share, marking a decline of 53.2% in one day [3] SelectQuote, Inc. (NYSE:SLQT) - The class period for SelectQuote is from September 9, 2020, to May 1, 2025, with a lead plaintiff deadline of October 10, 2025 [3] - On May 1, 2025, the U.S. Department of Justice filed a complaint against SelectQuote, alleging the company received "tens of millions of dollars" in illegal kickbacks from health insurance companies from 2016 to 2021 [3] - The complaint claims SelectQuote misled Medicare beneficiaries by stating it offered unbiased coverage comparisons while actually directing them to plans that paid SelectQuote the most, resulting in a stock price drop of $0.61, or 19.2%, to close at $2.56 per share on the same day [3][4]

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. on behalf of investors who purchased its securities during the specified class period, following disappointing trial results that led to a significant drop in stock price [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Johnson Fistel, PLLP, representing investors who bought Altimmune securities between August 10, 2023, and June 25, 2025 [1]. - Investors wishing to act as lead plaintiffs must file their motion by October 6, 2025 [1][2]. Group 2: Trial Results and Stock Impact - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [3]. - The stock price of Altimmune plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in just one day [3].

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2]. - The company's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant decline of 53.2% in just one day [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4].

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between August 10, 2023, and June 25, 2025 [1] Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2] - The company's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant decline of 53.2% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Company Overview - Altimmune is focused on developing a GLP-1 glucagon dual receptor agonist aimed at treating serious liver diseases, particularly MASH [1] - The drug, named pemvidutide, is designed to have direct effects on the liver while also providing metabolic benefits [1] Mechanism of Action - Glucagon has a direct effect on the liver, while GLP-1 contributes to metabolic benefits such as weight loss [2] - The optimal approach to treating MASH involves targeting the liver directly [2]

Company Overview - Altimmune is focused on developing a GLP-1 glucagon dual receptor agonist for the treatment of serious liver diseases, specifically MASH [1] - The drug, named pemvidutide, is designed to have direct effects on the liver while also providing metabolic benefits [1] Mechanism of Action - Glucagon has a direct effect on the liver, while GLP-1 contributes to metabolic benefits such as weight loss [2] - The optimal approach to treating MASH involves targeting the liver directly [2]

Summary of Altimmune Fireside Chat Company Overview - **Company**: Altimmune - **Focus**: Development of pemvidutide, a GLP-1/glucagon dual receptor agonist for treating serious liver diseases, particularly NASH (Non-Alcoholic Steatohepatitis) [3][4] Core Points and Arguments Pemvidutide and NASH - Pemvidutide is designed to have direct effects on the liver and provide metabolic benefits, primarily through weight loss [3][4] - Approximately 80% of NASH patients are overweight or obese, indicating that addressing both liver health and weight is crucial for treatment [4] - The drug shows significant reductions in liver fat, inflammation, and fibrosis, alongside weight loss [4] - Currently in a 48-week phase 2b trial for NASH, with 24-week data recently reported [5][6] Trial Design and Results - The phase 2b trial enrolled 212 patients with three treatment arms: placebo, 1.2 mg, and 1.8 mg of pemvidutide [6][7] - Class-leading NASH resolution was observed at the 24-week biopsy endpoint, exceeding results from other compounds [7][8] - Non-invasive tests showed robust anti-inflammatory and anti-fibrotic activity, with results indicating potential for FDA approval based on these tests [8][9] - The company plans to meet with the FDA to discuss transitioning from biopsy-based endpoints to non-invasive test-based endpoints for phase 3 trials [10][12] FDA Engagement and Future Plans - The company aims to align with the FDA on trial design, dose regimens, and endpoints during the end-of-phase 2 meeting [12][13] - Pemvidutide has shown excellent tolerability with no adverse event discontinuations, a significant advantage over other NASH treatments [15][17] - The company is preparing for phase 3 trials in NASH, expected to start in 2026 [5][10] Broader Implications and Market Position - The treatment landscape for NASH is evolving, with recent approvals for other drugs like semaglutide, which primarily focuses on metabolic components [23][24] - The combination of direct liver effects and weight loss in pemvidutide is positioned as a unique advantage over existing therapies [24][25] - The company is also exploring the use of pemvidutide in treating Alcohol Use Disorder (AUD) and Alcoholic Liver Disease (ALD), with ongoing trials [34][36] Additional Important Insights - The FDA has accepted applications for non-invasive tests, indicating a shift towards less invasive methods for evaluating liver health [9][10] - Pemvidutide's weight loss efficacy at the 2.4 mg dose was reported at 15.6% over 48 weeks, with potential for greater weight loss over longer periods [26][27] - The drug's ability to preserve lean mass during weight loss is highlighted as a critical factor, especially for older patients [28][29] - The company has received fast track status for AUD, emphasizing its commitment to addressing serious conditions related to obesity [39] Conclusion Altimmune is strategically positioned in the NASH treatment landscape with pemvidutide, focusing on both liver health and weight loss. The upcoming phase 3 trials and FDA meetings are critical milestones for the company's future in addressing serious liver diseases and related conditions.

Core Insights - The article discusses Stephen's unique approach to analyzing healthcare and tech stocks using his proprietary "Dizzy Framework," which aims to mitigate common behavioral errors in investment decision-making [1] Group 1: Investment Framework - The "Dizzy Framework" is designed to counteract behavioral biases such as chasing market noise and adhering too rigidly to prior beliefs [1] - The framework emphasizes the importance of the quality and timing of information, promoting a patient and disciplined investment approach [1] - Stephen's analysis translates complex scientific and market dynamics into actionable investment theses [1] Group 2: Influences and Background - Stephen's background includes experience as a Registered Nurse (RN) and an MBA, which informs his investment analysis [1] - Influences on Stephen's investment philosophy include concepts from "Superforecasting" and "Fooled by Randomness," highlighting a probabilistic approach to predictions [1] Group 3: Personal Interests - In his personal time, Stephen enjoys family activities, managing a fantasy baseball team, and contemplating existential questions [1]

Altimmune (NasdaqGM:ALT) FY Conference September 09, 2025 08:30 AM ET Speaker0Back to h c Wainwright's twenty seventh annual global investor conference held on September 2025. My name is Patrick Trucchio. I'm a senior health care analyst at h c Wainwright. That said, it's my pleasure to introduce our next company, Altimmune, a late stage biopharmaceutical company focused on developing novel peptide based therapeutics for liver and cardiometabolic diseases. Company's lead program is pembidutide, a GLP-one gl ...